Significant incidence of braf p.V600E mutations in esophageal cancer sets the stage for potential use of tyrosine kinase inhibitors - Rajasooriyar, C.; Moorthy, T.; Ranatunge, N.; Ginige, A.; Surenthirakumaran, R. (Jaffna Medical Association, 2020)
Keywords: Esophageal cancer; Tyrosine kinase inhibitors; Mutation